Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $50.00 by Analysts at Truist Financial
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective dropped by equities researchers at Truist Financial from $90.00 to $50.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 434.19% from the company’s previous close. […]
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price objective dropped by equities researchers at Truist Financial from $90.00 to $50.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 434.19% from the company’s previous close. […]
